Why Do Sponsors Terminate Clinical Trials...and at What Cost?
A review on what causes the early termination of clinical studies and what sponsors can do to improve their pipeline productivity and prevent ceasing development.
To say that biopharmaceutical organizations invest heavily in developing new drugs is an understatement. After accounting for the cost of failed trials and adding in the cost of discovery, the total cost to bring a new molecule to market may exceed $1 billion.
Download the white paper below for analysis on the causes and financial impact of early termination of clinical studies –information that can help sponsors significantly reduce relative risk and improve pipeline productivity.
Related Content
Looking for exclusive insight?
